SEGMENT AND ENTERPRISE-WIDE INFORMATION

12 Months Ended

Apr. 01, 2017

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

SEGMENT AND ENTERPRISE-WIDE INFORMATION

We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:

• Japan

• EMEA

• North America Plasma

• All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

During the first quarter of fiscal 2017, management reorganized its operating segments such that certain components of All Other are now reported as components of EMEA. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2017. These changes did not have an impact on our ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and asset impairments. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year, therefore segment information is presented on this basis.

Selected information by business segment is presented below:

(In thousands)	2017			2016			2015
Net revenues
Japan	$	74,695		$	84,270		$	83,547
EMEA	198,396			204,192			219,153
North America Plasma	309,718			279,803			240,705
All Other	316,771			342,249			340,427
Net revenues before foreign exchange impact	899,580			910,515			883,832
Effect of exchange rates	(13,464		)	(1,683		)	26,541
Net revenues	$	886,116		$	908,832		$	910,373

(In thousands)	2017			2016			2015
Segment operating income
Japan	$	32,906		$	38,280		$	36,843
EMEA	49,105			47,168			60,101
North America Plasma	105,253			109,220			89,092
All Other	109,296			120,562			131,471
Segment operating income	296,560			315,230			317,507
Corporate operating expenses	176,372			199,072			193,910
Effect of exchange rates	(4,772		)	3,546			13,906
Restructuring and turnaround costs	34,337			42,185			69,697
Deal amortization	27,107			28,958			30,184
Impairment of assets	73,353			97,230			—
Contingent consideration income	—			(4,727		)	(2,918		)
Operating (loss) income	$	(19,381	)	$	(43,942	)	$	40,540

(In thousands)	2017		2016		2015
Depreciation and amortization
Japan	$	827	$	774	$	767
EMEA	4,255		5,146		5,045
North America Plasma	13,022		12,944		11,229
All Other	71,629		71,047		69,012
Total depreciation and amortization (excluding impairment charges)	$	89,733	$	89,911	$	86,053

(In thousands)	April 1, 2017		April 2, 2016		March 28, 2015
Long-lived assets(1)
Japan	$	21,412	$	33,159	$	31,810
EMEA	63,854		63,861		66,223
North America Plasma	142,164		116,001		101,272
All Other	96,432		124,613		122,643
Total long-lived assets	$	323,862	$	337,634	$	321,948
(1)Long-lived assets are comprised of property, plant and equipment.

Long-lived assets in our principle operating regions are as follows:

(In thousands)	April 1, 2017		April 2, 2016		March 28, 2015
United States	$	241,610	$	231,744	$	208,439
Japan	1,691		2,022		1,618
Europe	12,952		18,672		27,786
Asia	34,174		40,235		39,032
Other	33,435		44,961		45,073
Total	$	323,862	$	337,634	$	321,948

In fiscal 2017, we organized our current products into four business units for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units, however, no other financial information is currently available on this basis.

Net revenues by business unit are as follows:

(In thousands)	2017		2016		2015
Plasma	410,727		381,776		352,911
Blood Center	303,890		355,108		386,147
Cell Processing	105,376		112,483		120,434
Hemostasis Management	66,123		59,465		50,881
Net revenues	$	886,116	$	908,832	$	910,373

Net revenues generated in our principle operating regions are as follows:

(In thousands)	2017		2016		2015
United States	$	522,686	$	519,440	$	494,788
Japan	79,266		81,411		88,298
Europe	166,007		187,725		215,575
Asia	109,858		111,758		102,095
Other	8,299		8,498		9,617
Total	$	886,116	$	908,832	$	910,373